Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies
• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Vogel, A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Using regression analysis to predict the future energy consumption of a supermarket in the UK - Braun, M.R. ELSEVIER, 2014, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:59 ; year:2017 ; pages:54-60 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ctrv.2017.04.007 |
|---|
| Katalog-ID: |
ELV035869216 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035869216 | ||
| 003 | DE-627 | ||
| 005 | 20230625205914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2017.04.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017010000008.pica |
| 035 | |a (DE-627)ELV035869216 | ||
| 035 | |a (ELSEVIER)S0305-7372(17)30065-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 620 |q VZ |
| 082 | 0 | 4 | |a 150 |a 300 |q VZ |
| 084 | |a 77.52 |2 bkl | ||
| 100 | 1 | |a Vogel, A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. | ||
| 520 | |a • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. | ||
| 650 | 7 | |a Regorafenib |2 Elsevier | |
| 650 | 7 | |a Trifuridine/tipiracil |2 Elsevier | |
| 650 | 7 | |a Beyond second line combination therapy |2 Elsevier | |
| 650 | 7 | |a Reintroduction |2 Elsevier | |
| 650 | 7 | |a Metastatic colorectal cancer |2 Elsevier | |
| 700 | 1 | |a Hofheinz, R.D. |4 oth | |
| 700 | 1 | |a Kubicka, S. |4 oth | |
| 700 | 1 | |a Arnold, D. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Braun, M.R. ELSEVIER |t Using regression analysis to predict the future energy consumption of a supermarket in the UK |d 2014 |g Amsterdam [u.a.] |w (DE-627)ELV01225004X |
| 773 | 1 | 8 | |g volume:59 |g year:2017 |g pages:54-60 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2017.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 77.52 |j Differentielle Psychologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 59 |j 2017 |h 54-60 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a v av |
|---|---|
| matchkey_str |
vogelahofheinzrdkubickasarnoldd:2017----:ramndcsosneattcooetlacreodisadeod |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
77.52 |
| publishDate |
2017 |
| allfields |
10.1016/j.ctrv.2017.04.007 doi GBVA2017010000008.pica (DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Vogel, A. verfasserin aut Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier Hofheinz, R.D. oth Kubicka, S. oth Arnold, D. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:59 year:2017 pages:54-60 extent:7 https://doi.org/10.1016/j.ctrv.2017.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 59 2017 54-60 7 045F 610 |
| spelling |
10.1016/j.ctrv.2017.04.007 doi GBVA2017010000008.pica (DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Vogel, A. verfasserin aut Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier Hofheinz, R.D. oth Kubicka, S. oth Arnold, D. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:59 year:2017 pages:54-60 extent:7 https://doi.org/10.1016/j.ctrv.2017.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 59 2017 54-60 7 045F 610 |
| allfields_unstemmed |
10.1016/j.ctrv.2017.04.007 doi GBVA2017010000008.pica (DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Vogel, A. verfasserin aut Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier Hofheinz, R.D. oth Kubicka, S. oth Arnold, D. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:59 year:2017 pages:54-60 extent:7 https://doi.org/10.1016/j.ctrv.2017.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 59 2017 54-60 7 045F 610 |
| allfieldsGer |
10.1016/j.ctrv.2017.04.007 doi GBVA2017010000008.pica (DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Vogel, A. verfasserin aut Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier Hofheinz, R.D. oth Kubicka, S. oth Arnold, D. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:59 year:2017 pages:54-60 extent:7 https://doi.org/10.1016/j.ctrv.2017.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 59 2017 54-60 7 045F 610 |
| allfieldsSound |
10.1016/j.ctrv.2017.04.007 doi GBVA2017010000008.pica (DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Vogel, A. verfasserin aut Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies 2017transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. • Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier Hofheinz, R.D. oth Kubicka, S. oth Arnold, D. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:59 year:2017 pages:54-60 extent:7 https://doi.org/10.1016/j.ctrv.2017.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 59 2017 54-60 7 045F 610 |
| language |
English |
| source |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:59 year:2017 pages:54-60 extent:7 |
| sourceStr |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:59 year:2017 pages:54-60 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Differentielle Psychologie |
| institution |
findex.gbv.de |
| topic_facet |
Regorafenib Trifuridine/tipiracil Beyond second line combination therapy Reintroduction Metastatic colorectal cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| authorswithroles_txt_mv |
Vogel, A. @@aut@@ Hofheinz, R.D. @@oth@@ Kubicka, S. @@oth@@ Arnold, D. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01225004X |
| dewey-sort |
3610 |
| id |
ELV035869216 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035869216</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205914.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2017.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035869216</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(17)30065-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vogel, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Regorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trifuridine/tipiracil</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beyond second line combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Reintroduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic colorectal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofheinz, R.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kubicka, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:54-60</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2017.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2017</subfield><subfield code="h">54-60</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Vogel, A. |
| spellingShingle |
Vogel, A. ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| authorStr |
Vogel, A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01225004X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 620 - Engineering & allied operations 150 - Psychology 300 - Social sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer Elsevier |
| topic |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer |
| topic_unstemmed |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer |
| topic_browse |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Regorafenib Elsevier Trifuridine/tipiracil Elsevier Beyond second line combination therapy Elsevier Reintroduction Elsevier Metastatic colorectal cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r h rh s k sk d a da |
| hierarchy_parent_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| hierarchy_parent_id |
ELV01225004X |
| dewey-tens |
610 - Medicine & health 620 - Engineering 150 - Psychology 300 - Social sciences, sociology & anthropology |
| hierarchy_top_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01225004X |
| title |
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| ctrlnum |
(DE-627)ELV035869216 (ELSEVIER)S0305-7372(17)30065-8 |
| title_full |
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| author_sort |
Vogel, A. |
| journal |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| journalStr |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
54 |
| author_browse |
Vogel, A. |
| container_volume |
59 |
| physical |
7 |
| class |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Vogel, A. |
| doi_str_mv |
10.1016/j.ctrv.2017.04.007 |
| dewey-full |
610 620 150 300 |
| title_sort |
treatment decisions in metastatic colorectal cancer – beyond first and second line combination therapies |
| title_auth |
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| abstract |
• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. |
| abstractGer |
• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. |
| abstract_unstemmed |
• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies |
| url |
https://doi.org/10.1016/j.ctrv.2017.04.007 |
| remote_bool |
true |
| author2 |
Hofheinz, R.D. Kubicka, S. Arnold, D. |
| author2Str |
Hofheinz, R.D. Kubicka, S. Arnold, D. |
| ppnlink |
ELV01225004X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.ctrv.2017.04.007 |
| up_date |
2024-07-06T18:42:03.201Z |
| _version_ |
1803856194517860352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035869216</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205914.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2017.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035869216</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(17)30065-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vogel, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Following disease progression after standard first- and second-line combination chemotherapy with monoclonal antibodies, many patients have a good performance status and a significant proportion are willing to undergo further therapy. • Choices of treatment beyond the second-line setting for mCRC are therefore becoming increasingly important. • Regorafenib significantly improved OS compared with placebo in two pivotal phase III trials (CORRECT and CONCUR) in chemo-refractory mCRC patients. TAS-102, an oral fluoropyrimidine, also resulted in significantly improved OS versus placebo in the phase III trial RECOURSE, which was conducted in a similar patient population to CONCUR and CORRECT. • Reintroduction of previously administered therapy is another valid and commonly used approach, especially for those regimens which were discontinued before progression. • This review aims to provide guidance for mCRC treatment beyond second-line combination therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Regorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Trifuridine/tipiracil</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beyond second line combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Reintroduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic colorectal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofheinz, R.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kubicka, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnold, D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:54-60</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2017.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2017</subfield><subfield code="h">54-60</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4000187 |